Tumores Mamários

Análise de longo prazo de estudo randomizado de fase 2 | Fulvestrante com capivasertibe vs. placebo após recorrência ou progressão do inibidor de aromatase no câncer de mama metastático, positivo para receptor de estrogênio e negativo para HER2.

12 Jul, 2022 | 11:13h

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial – The Lancet Oncology

Comunicado de imprensa: New phase of breast cancer drug trial provides fresh hope for patients with incurable disease – Cardiff University

Estudo original: Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial – The Lancet Oncology

 

---

M-A | Fatores de risco da cardiotoxicidade induzida por antraciclina no tratamento do câncer de mama.

8 Jul, 2022 | 10:57h

Risk Factors for Anthracycline-Induced Cardiotoxicity in Breast Cancer Treatment: A Meta-Analysis – Frontiers in Oncology

 

---

Estudo randomizado | Atezolizumabe com terapia neoadjuvante antirreceptor 2 do fator de crescimento epidérmico humano e quimioterapia no câncer de mama inicial positivo para receptor 2 do fator de crescimento epidérmico humano.

4 Jul, 2022 | 11:29h

Atezolizumab With Neoadjuvant Anti–Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial – Journal of Clinical Oncology

Comentário: Atezolizumab Does Not Improve pCR in HER2-Positive Early Breast Cancer – OncLive

 

Comentário no Twitter

Presented at #ESMO VP6, IMpassion050 is now published on JCO. The addition of atezo to neoadjuvant ddAC-T+HP doesn’t increase pCR rates in HER2+ EBC, neither in ITT (left) nor PD-L1+ (right). Significant increase in toxicity with atezo, including 5 deaths.https://t.co/fL6mEjKTTS pic.twitter.com/2fYStkh8Zt

— Paolo Tarantino (@PTarantinoMD) June 28, 2022

 

---

Diretriz NCCN atualizada | Câncer de mama.

21 Jun, 2022 | 12:58h

Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology – Journal of the National Comprehensive Cancer Network

---

Estudo de coorte | Associação do rastreamento com tomossíntese digital de mama vs. mamografia digital com o risco de câncer de mama avançado e invasivo.

19 Jun, 2022 | 17:12h

Association of Screening With Digital Breast Tomosynthesis vs Digital Mammography With Risk of Interval Invasive and Advanced Breast Cancer – JAMA (gratuito por tempo limitado)

Editorial: Digital Breast Tomosynthesis and Detection of Interval Invasive and Advanced Breast Cancers – JAMA (gratuito por tempo limitado)

Comunicado de imprensa: 3-D Mammography Technique Benefits Some Women, Not All – University of California San Francisco

---

Breve resumo dos principais fatos atuais e recomendações | Linfadenopatia regional após vacinação contra COVID-19 em pacientes com ou sem suspeita de câncer de mama.

19 Jun, 2022 | 14:21h

Regional Lymphadenopathy Following COVID-19 Vaccination in Patients with or Suspicious of Breast Cancer: A Quick Summary of Current Key Facts and Recommendations – Korean Journal of Radiology

Conteúdos relacionados:

2 Case Series and Guidance | Lymphadenopathy in COVID-19 Vaccine Recipients

Axillary lymphadenopathy at the time of COVID-19 vaccination: ten recommendations from the European Society of Breast Imaging (EUSOBI) – Insights into Imaging

Covid-19: Schedule breast screening before vaccine or 4 to 6 weeks after to avoid false positives, says guidance – The BMJ

Frequency and outcomes of MRI-detected axillary adenopathy following COVID-19 vaccination – European Radiology

Regional lymphadenopathy following COVID-19 vaccination: Literature review and considerations for patient management in breast cancer care – European Journal of Cancer

---

DNA circulante de tumor e recorrência tardia em câncer de mama de alto risco, positivo para receptor de hormônio e negativo para receptor do fator de crescimento epidérmico humano 2.

19 Jun, 2022 | 13:04h

Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer – Journal of Clinical Oncology

Editorial: Can a Late Interception by Circulating Tumor DNA Deliver a Win in Estrogen Receptor–Positive Early Breast Cancer?

Comentário: Tumor DNA Assay Portends Metastatic Breast Cancer Recurrence Months in Advance — First evidence for patients in late adjuvant setting, years after initial diagnosis – MedPage Today (necessário cadastro gratuito)

 

Comentário no Twitter

103 women in long-term remission from high-risk HR+/HER2- breast cancer had customized monitoring of recurrence based on ctDNA seq for tumour-associated mut. Among 8 pts MRD+ pts, 6 developed distant recurrence at a median 12.4 mo after ctDNA positivity https://t.co/aX1ruLCSbb

— NatureRevClinOncol (@NatRevClinOncol) June 9, 2022

 

---

Estudo de coorte | Qualidade de vida de longo prazo em pacientes com câncer de mama após conservação da mama vs. mastectomia e reconstrução.

16 Jun, 2022 | 12:47h

Long-term Quality of Life in Patients With Breast Cancer After Breast Conservation vs Mastectomy and Reconstruction – JAMA Surgery (link para o resumo – $ para o texto completo)

Comentários:

Long-Term QOL Examined for Surgical Choices in Breast Cancer – HealthDay

Improved Long-Term Quality-of-Life Measures in Women Undergoing Breast Conservation vs Mastectomy and Reconstruction for Early Breast Cancer – The ASCO Post

 

Comentário no Twitter

Survey of #breastcancer survivors after treatment found:
1. Breast satisfaction and physical well-being similar with lumpectomy+rads or mastectomy+reconstruction (no rads)
2. Psychosocial well-being and sexual well-being better with lumpectomy+rads https://t.co/tPh9Pt4gYx

— JAMA Surgery (@JAMASurgery) April 14, 2022

 

---

#ASCO22 – Estudo randomizado | Trastuzumabe deruxtecam no câncer de mama avançado previamente tratado com baixo HER2.

13 Jun, 2022 | 14:45h

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer – New England Journal of Medicine (link para o resumo – $ para o texto completo)

Comentário: Trastuzumab Deruxtecan Cuts Risk of Disease Progression or Death by 50% for Patients With HER2-Low Metastatic Breast Cancer – AJMC

 

Comentário no Twitter

DESTINY-Breast04: In a phase 3 trial, trastuzumab deruxtecan resulted in longer progression-free and overall survival than the physician’s choice of chemo among patients with HER2-low breast cancer. #ASCO22 https://t.co/bgheQ1yolb pic.twitter.com/nfRMcIh9Ly

— NEJM (@NEJM) June 5, 2022

 

---

Estudo randomizado de fase 2 | Eficácia do epigalocatecina-3-galato na prevenção de dermatites em pacientes com câncer de mama sob radioterapia pós-cirúrgica.

6 Jun, 2022 | 11:11h

Efficacy of Epigallocatechin-3-Gallate in Preventing Dermatitis in Patients With Breast Cancer Receiving Postoperative Radiotherapy: A Double-Blind, Placebo-Controlled, Phase 2 Randomized Clinical Trial – JAMA Dermatology (gratuito por tempo limitado)

Resumo visual: Efficacy of Epigallocatechin-3-Gallate on Dermatitis in Patients With Breast Cancer Receiving Postoperative Radiotherapy

---